



(12) Translation of
European patent specification

(11) NO/EP 3702373 B1

NORWAY

(19) NO

(51) Int Cl.

C07K 16/28 (2006.01)

A61P 25/00 (2006.01)

A61P 35/00 (2006.01)

A61K 39/395 (2006.01)

A61P 31/12 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.11.14
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.08.24
(86)	European Application Nr.	20154386.5
(86)	European Filing Date	2013.09.13
(87)	The European Application's Publication Date	2020.09.02
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
	Designated Extension States:	BA; ME
(62)	Divided application	EP3044234, 2013.09.13
(73)	Proprietor	BeiGene Switzerland GmbH, Aeschengraben 27, 4051 Basel, Sveits
(72)	Inventor	SONG, Jing, No.30 Science Park Road Zhongguancun Life Science Park, Changping, Beijing 102206, Kina LI, Kang, No.30 Science Park Road Zhongguancun Life Science Park, Changping, Beijing 102206, Kina ZHANG, Tong, No.30 Science Park Road Zhongguancun Life Science Park, Changping, Beijing 102206, Kina XU, Lanlan, No.30 Science Park Road Zhongguancun Life Science Park, Changping, Beijing 102206, Kina LIU, Qi, No.30 Science Park Road Zhongguancun Life Science Park, Changping, Beijing 102206, Kina PENG, Hao, No.30 Science Park Road Zhongguancun Life Science Park, Changping, Beijing 102206, Kina
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
(56)	References Cited:	WO-A2-2010/089411, WO-A1-2006/121168, WO-A1-2008/156712, WO-A1-2012/135408 WO-A1-2012/145493, M. SZNOL ET AL: "Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer", CLINICAL CANCER RESEARCH, vol. 19, no. 5, 1 March 2013 (2013-03-01), pages 1021-1034, XP055123957, ISSN: 1078-0432, DOI: 10.1158/1078- 0432.CCR-12-2063 BERGER RAANAN ET AL: "Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 10, 15 May 2008 (2008-05-15), pages 3044-3051, XP002524925, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-4079

WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151-162, XP004461859, ISSN: 0022-2836, DOI: 10.1006/JMBI.1999.3141

DAVID M. DORFMAN ET AL: "Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma", AMERICAN JOURNAL OF SURGICAL PATHOLOGY., vol. 30, no. 7, 1 July 2006 (2006-07-01), pages 802-810, XP055343182, US ISSN: 0147-5185, DOI: 10.1097/01.pas.0000209855.28282.ce

JAMES W. STAVE ET AL.: "Antibody and Antigen Contact Residues Define Epitope and Paratope size and Structure", THE JOURNAL OF IMMUNOLOGY, vol. 191, 1 January 2013 (2013-01-01), pages 1428-1435, XP055303910,

M. J. FULLER ET AL: "Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 37, 26 August 2013 (2013-08-26), pages 15001-15006, XP055343159, US ISSN: 0027-8424, DOI: 10.1073/pnas.1312772110

OMID HAMID ET AL: "Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, no. 2, 11 July 2013 (2013-07-11), pages 134-144, XP055182016, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1305133

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

EP3702373

1

Patentkrav

- 5 **1.** Antistoff omfattende et antistoffantigenbindende domene som binder til human PD-1, og omfatter en variabel tungkjederegion (Vh) omfattende SEQ ID NO: 24, og en variabel lettkjederegion (Vk) omfattende SEQ ID NO: 26, hvori antistoffet er monospesifikt.
- 10 **2.** Antistoffet ifølge krav 1, omfattende et IgG4-konstant domene omfattende et hvilket som helst av SEQ ID NO: 83-88.
- 15 **3.** Antistoffet ifølge krav 1, omfattende et IgG4-konstant domene omfattende SEQ ID NO: 87 eller SEQ ID NO: 88.
- 20 **4.** Antistoffet ifølge krav 1, omfattende et IgG4-konstant domene omfattende SEQ ID NO: 88.
- 25 **5.** Antistoff omfattende et antistoffantigenbindende domene som binder til humant PD-1, og omfatter en variabel tungkjederegion (Vh) omfattende SEQ ID NO: 24, og en variabel lettkjederegion (Vk) omfattende SEQ ID NO: 26 for anvendelse i terapi.
- 30 **6.** Antistoffet for anvendelse ifølge krav 5 for anvendelse i behandling av kreft eller virusinfeksjon hos et menneske.
- 7.** Antistoffet for anvendelse ifølge krav 6 i behandling av kreft hos et menneske.
- 8.** Antistoffet for anvendelse ifølge et hvilket som helst av kravene 5 til 7, omfattende et IgG4-konstant domene omfattende et hvilket som helst av SEQ ID NO: 83-88.
- 9.** Antistoffet for anvendelse ifølge et hvilket som helst av kravene 5 til 7, omfattende et IgG4-konstant domene omfattende SEQ ID NO: 87 eller SEQ ID NO: 88.

EP3702373

2

10. Antistoffet for anvendelse ifølge et hvilket som helst av kravene 5 til 7, omfattende et IgG4-konstant domene omfattende SEQ ID NO: 88.